drugset / Trial / NCT00928486

A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma

NCT00928486

Phase 3 Completed 25 enrolled Celgene Corporation
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of lenalidomide with dexamethasone in Japanese patients with previously treated multiple myeloma.

Timeline

Start
2009-04-28
Primary completion
2010-09-10
Completion
2010-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 mg Oral
Subject Lenalidomide Other / unclassified 15 mg Oral
Subject Lenalidomide Other / unclassified 25 mg Oral

Indications